Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018
BOSTON--(BUSINESS WIRE)--Feb. 28, 2018--
Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with severe neurological diseases such as multiple
sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral
sclerosis (ALS) under FDA Fast Track designation, announced today that
it will report its financial results for the fourth quarter and
year-ended December 31, 2017 on Wednesday, March 7, 2018 before the U.S.
financial markets open. The Company will host a conference call and
webcast at 9:00 a.m. ET to discuss fourth quarter and full year 2017
financial results and provide a business update. Individuals interested
in participating in the call should dial (855) 780-7202 (U.S. and
Canada) or (631) 485-4874 (International).
A live webcast may be accessed in the Investors section of the Company's
website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments for cramps and
spasticity associated with the severe neurological diseases of ALS, MS
and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The
Company’s lead candidate, FLX-787, is being developed under Fast Track
designation for the treatment of severe muscle cramps associated with
ALS. Flex Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Christoph Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180228006449/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications